OMNIPAQUE 210 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Omnipaque 210, and what generic alternatives are available?
Omnipaque 210 is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in OMNIPAQUE 210 is iohexol. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iohexol profile page.
Summary for OMNIPAQUE 210
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 98 |
| Clinical Trials: | 25 |
| Patent Applications: | 3,506 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | OMNIPAQUE 210 at DailyMed |
Recent Clinical Trials for OMNIPAQUE 210
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Claire Bourgeois | Phase 4 |
| Fédération des médecins résidents du Québec | Phase 4 |
| Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal | Phase 4 |
Pharmacology for OMNIPAQUE 210
| Drug Class | Radiographic Contrast Agent |
| Mechanism of Action | X-Ray Contrast Activity |
Anatomical Therapeutic Chemical (ATC) Classes for OMNIPAQUE 210
US Patents and Regulatory Information for OMNIPAQUE 210
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | OMNIPAQUE 210 | iohexol | INJECTABLE;INJECTION | 018956-006 | Jun 30, 1989 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for OMNIPAQUE 210
See the table below for patents covering OMNIPAQUE 210 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Norway | 156317 | ⤷ Try a Trial | |
| South Africa | 7004404 | ⤷ Try a Trial | |
| Spain | 482131 | ⤷ Try a Trial | |
| Singapore | 5784 | ⤷ Try a Trial | |
| Israel | 57713 | PROCESS FOR THE PREPARATION OF A STERILE INJECTABLE PHYSIOLOGICALLY ACCEPTABLE SOLUTION OF AN X-RAY CONTRAST AGENT AND SOLUTIONS OF THE X-RAY CONTRAST AGENT AND A BUFFER | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
